ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-IL-6-monoclonal-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-IL-6-monoclonal-antibody
7
trial(s) found.
NCT05927571
Haem
Phase 1
Recruiting
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma (
GO43979
)
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,FcRH5-targeting
+ anti-IL-6 monoclonal antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3181 - Prahran - The Alfred Hospital
NCT05583617
Haem
Phase 1 / Phase 2
Recruiting
A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma (
PLYCOM
)
CELMoD agent
Cevostamab
Dexamethasone
Iberdomide
Lenalidomide
Tocilizumab
anti-IL-6 monoclonal antibody
bispecific T-cell engager,FcRH5-targeting
cancer therapy
cancer therapy,FcRH5-targeting
cancer therapy,IL-6-targeting
cancer therapy,cereblon-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,FcRH5-targeting
immuno-oncology therapy,IL-6-targeting
immunomodulatory imide drug
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ anti-IL-6 monoclonal antibody
Multiple myeloma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
+ anti-IL-6 monoclonal antibody
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
+ anti-IL-6 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3168 - Clayton - Monash Medical Centre
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (COMPLETED)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-IL-6 monoclonal antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ anti-IL-6 monoclonal antibody
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000620628
Haem
Phase 2
Recruiting
NHL38 Epco-Sandwich: A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with relapsed large B-cell lymphoma.
bispecific T-cell engager,CD20-targeting
+ anti-IL-6 monoclonal antibody
Diffuse large B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Recruitment Country and State
VIC (5)
NSW (3)
QLD (3)
WA (2)
NZ (1)
ACT (1)
SA (1)
TAS (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (4)
Phase 2 (1)
Trial Type
Haem (4)
Advanced (2)
Paed (1)
Cancer Therapy Class
IL-6
100%
CD20
43%
FcRH5
29%
PD-1/PD-L1
29%
PD-L1
29%
VEGF
29%
BCMA
14%
cereblon
14%
Bcl2
14%
CTLA4
14%
HIF2a
14%
LAG3
14%
PD-1
14%
PPAR-alpha
14%
TIGIT
14%
AKT
14%
CD40
14%
CDK4
14%
CDK6
14%
ERBB2
14%
ER
14%
LIV1
14%
PI3Kalpha
14%
Trop2
14%
oestrogen axis
14%
Facility
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (2)
3168 - Clayton - Monash Medical Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3181 - Prahran - The Alfred Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
Multiple myeloma
Plasma cell disorder
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Solid tumour
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
Breast cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy